95 results on '"Brahe, Cecilie Heegaard"'
Search Results
2. Occurrence and Prediction of Flare After Tapering of Tumor Necrosis Factor Inhibitors in Patients With Axial Spondyloarthritis
3. Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching.
4. Using a DAS28-CRP-steered treat-to-target strategy does not eliminate subclinical inflammation as assessed by ultrasonography in rheumatoid arthritis patients in longstanding clinical remission
5. Occurrence and prediction of flare after tapering of TNF inhibitors in patients with axial spondyloarthritis
6. Second and third TNF inhibitors in European patients with axial spondyloarthritis: Effectiveness and impact of the reason for switching
7. Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors
8. Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care:characteristics and predictors
9. Tapering of TNF inhibitors in axial spondyloarthritis in routine care-2-year clinical and MRI outcomes and predictors of successful tapering
10. Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration
11. Tapering of TNF inhibitors in axial spondyloarthritis in routine care — 2-year clinical and MRI outcomes and predictors of successful tapering
12. Doppler ultrasound predicts successful discontinuation of biological DMARDs in rheumatoid arthritis patients in clinical remission
13. Doppler ultrasound predicts successful discontinuation of biological DMARDs in rheumatoid arthritis patients in clinical remission
14. Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment:routine care data from 13 registries in the EuroSpA collaboration
15. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment - Results from 12 countries in EuroSpA
16. Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration
17. Does Drug Effectiveness of 2nd and 3rd TNF Inhibitors in Patients with Psoriatic Arthritis Depend on the Reason for Withdrawal from the Previous Treatment? - Results from the EuroSpA Research Collaboration
18. Patient Reported Outcomes over 2 Years in Psoriatic Arthritis Patients Initiating Treatment with 1st, 2nd or 3rd TNF Inhibitor in Routine Care - Was PRO Remission Achieved? Results from the EuroSpA Collaboration
19. 6 and 12-month Drug Retention Rates and Treatment Outcomes in 941 Patients with Axial Spondyloarthritis Treated with Secukinumab in Routine Clinical Practice in 12 European Countries in the EuroSpA Research Collaboration Network
20. POOLED 6-MONTH TREATMENT OUTCOMES AND DRUG RETENTION RATES IN 1556 PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH SECUKINUMAB IN ROUTINE CLINICAL PRACTICE IN 12 EUROPEAN COUNTRIES IN THE EUROSPA RESEARCH COLLABORATION
21. TREATMENT RESPONSE AND DRUG RETENTION RATES IN 23,956 BIOLOGIC-NAIVE PATIENTS WITH AXIAL SPONDYLOARTHRITIS INITIATING TNFI TREATMENT - ROUTINE CARE DATA FROM 12 REGISTRIES IN THE EUROSPA COLLABORATION
22. DRUG RETENTION AND REMISSION RATES IN 14,261 BIOLOGIC-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS STARTING TNF INHIBITOR TREATMENT IN ROUTINE CARE - RESULTS FROM 12 REGISTRIES IN THE EUROSPA RESEARCH COLLABORATION
23. Secukinumab effectiveness in 1134 patients with psoriatic arthritis treated in routine clinical practice in 11 European countries in the EuroSpA research collaboration network
24. Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis
25. DOES DRUG EFFECTIVENESS OF 2ND AND 3RD TNF INHIBITORS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS DEPEND ON THE REASON FROM WITHDRAWAL FROM THE PREVIOUS TREATMENT?:RESULTS FROM THE EUROSPA RESEARCH COLLABORATION
26. POOLED 6-MONTH TREATMENT OUTCOMES AND DRUG RETENTION RATES IN 1556 PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH SECUKINUMAB IN ROUTINE CLINICAL PRACTICE IN 12 EUROPEAN COUNTRIES IN THE EUROSPA RESEARCH COLLABORATION
27. REMISSION AND DRUG RETENTION RATES OF SECUKINUMAB IN 1549 PATIENTS WITH PSORIATIC ARTHRITIS TREATED IN ROUTINE CARE:POOLED DATA FROM THE OBSERVATIONAL EUROSPA RESEARCH COLLABORATION NETWORK
28. DRUG RETENTION AND REMISSION RATES IN 14,261 BIOLOGIC-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS STARTING TNF INHIBITOR TREATMENT IN ROUTINE CARE – RESULTS FROM 12 REGISTRIES IN THE EUROSPA RESEARCH COLLABORATION
29. VALIDATION OF THE ADJUSTED MULTI-BIOMARKER DISEASE ACTIVITY SCORE FOR PREDICTING RISK OF RADIOGRAPHIC PROGRESSION FOR PATIENTS WITH RHEUMATOID ARTHRITIS
30. DOES DRUG EFFECTIVENESS OF 2ND AND 3RD TNF INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITIS DEPEND ON THE REASON FOR WITHDRAWAL FROM THE PREVIOUS TREATMENT?:RESULTS FROM THE EUROSPA RESEARCH COLLABORATION
31. Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment:routine care data from 12 registries in the EuroSpA collaboration
32. Drug Retention and Response Rates of TNFi Treatment in 21,470 Patients with Axial Spondyloarthritis Treated in Clinical Practice-Pooled Data from the Eurospa Research Network Collaboration
33. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment—results from 12 countries in EuroSpA
34. Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration
35. SAT0391 REMISSION AND DRUG RETENTION RATES OF SECUKINUMAB IN 1549 PATIENTS WITH PSORIATIC ARTHRITIS TREATED IN ROUTINE CARE – POOLED DATA FROM THE OBSERVATIONAL EUROSPA RESEARCH COLLABORATION NETWORK
36. FRI0404 POOLED 6-MONTH TREATMENT OUTCOMES AND DRUG RETENTION RATES IN 1556 PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH SECUKINUMAB IN ROUTINE CLINICAL PRACTICE IN 12 EUROPEAN COUNTRIES IN THE EUROSPA RESEARCH COLLABORATION
37. AB0752 DRUG RETENTION AND REMISSION RATES IN 14,261 BIOLOGIC-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS STARTING TNF INHIBITOR TREATMENT IN ROUTINE CARE – RESULTS FROM 12 REGISTRIES IN THE EUROSPA RESEARCH COLLABORATION
38. FRI0378 DOES DRUG EFFECTIVENESS OF 2ND AND 3RD TNF INHIBITORS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS DEPEND ON THE REASON FROM WITHDRAWAL FROM THE PREVIOUS TREATMENT? – RESULTS FROM THE EUROSPA RESEARCH COLLABORATION
39. THU0065 VALIDATION OF THE ADJUSTED MULTI-BIOMARKER DISEASE ACTIVITY SCORE FOR PREDICTING RISK OF RADIOGRAPHIC PROGRESSION FOR PATIENTS WITH RHEUMATOID ARTHRITIS
40. SAT0614 DOES DRUG EFFECTIVENESS OF 2ND AND 3RD TNF INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITIS DEPEND ON THE REASON FOR WITHDRAWAL FROM THE PREVIOUS TREATMENT? – RESULTS FROM THE EUROSPA RESEARCH COLLABORATION
41. SAT0625 TREATMENT RESPONSE AND DRUG RETENTION RATES IN 23,956 BIOLOGIC-NAÏVE PATIENTS WITH AXIAL SPONDYLOARTHRITIS INITIATING TNFI TREATMENT – ROUTINE CARE DATA FROM 12 REGISTRIES IN THE EUROSPA COLLABORATION
42. Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis
43. Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care – 2-year outcomes and predictors
44. Development of an Adjusted Multi-Biomarker Disease Activity (MBDA) Score for Rheumatoid Arthritis (RA) That Accounts for Age, Sex and Adiposity, with Subsequent Evaluation of Ability to Predict Risk for Radiographic Damage
45. High Multi-Biomarker Disease Activity Score Is Associated with High Risk of Radiographic Progression in Six Cohorts
46. Validating Rheumatoid Arthritis Remission Using the Patients' Perspective:Results from a Special Interest Group at OMERACT 2016
47. Validating Rheumatoid Arthritis Remission Using the Patients’ Perspective: Results from a Special Interest Group at OMERACT 2016
48. Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care – 2-year outcomes and predictors.
49. Multi-Biomarker Disease Activity (MBDA) Score and Prediction of Radiographic Progression in a Randomized Study of Patients with Early RA Treated with Methotrexate Alone or with Adalimumab
50. Dose Reduction or Discontinuation of Biological Therapy in Patients with Rheumatoid Arthritis in Remission:1-Year Results of a Guideline-Directed Longitudinal Cohort Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.